// App-Quantinova.ai

e21064 : Tyrosine kinase inhibitor (TKI) cessation in advanced non-small-cell lung cancer (aNSCLC) for improved detection of EGFR-mutated (EGFRm) circulating tumor DNA (ctDNA).

Researchers

Presenter

  • Samer Tabchi

Principal Investigators

  • Stephanie Forte

  • Raafat Alameddine

  • Aline Khazaka

  • Marie Florescu

  • Xiaoduan Weng

  • Mustapha Tehfe

  • Normand Blais

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Saint Joseph University, Beirut, Lebanon

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

Locations

  • United States

  • Canada

  • Lebanon

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating DNA

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved